Easton honored with inaugural AACR Outstanding Investigator Award in Breast Cancer Research

December 11, 2008

SAN ANTONIO - Douglas Easton, Ph.D., whose international studies in breast cancer explained the genetic patterns and causes of the BRCA1 and BRCA2 gene mutations which indicate a person's risk for breast cancer, has been selected to receive the inaugural American Association for Cancer Research (AACR) Outstanding Investigator Award in Breast Cancer Research.

This award, funded by Susan G. Komen for the Cure, recognizes an investigator whose novel and significant work has had or may have a far-reaching impact on the causes, detection, diagnosis, treatment or prevention of breast cancer.

Easton, professor of genetic epidemiology and director of the Cancer Research UK Genetic Epidemiology Unit in the Department of Public Health and Primary Care at the University of Cambridge, has been selected for his national and international studies of the genetic causes and patterns of breast cancer. As a result of his work, Easton established the Breast Cancer Linage Consortium, which provided the first estimates of breast and ovarian cancer risk in BRCA1 mutation carriers and developed a risk model that is used daily in clinics worldwide.

Most recently, Easton assisted in identifying five breast cancer genes located in specific areas on the chromosome which impact breast cancer susceptibility, none of which had previously been associated with breast cancer: FGFR2, TNRC9, MAP3K1, LSP1 and a locus on 8q. Subsequently, he demonstrated how variations in these loci are associated with increased risk of breast cancer in BRCA mutation carriers. These observations may become important in counseling women who carry the BRCA mutation, and will be important for risk stratification in the general population.

Easton received Bachelor of Arts and Master of Arts degrees in mathematics from the University of Cambridge. He earned a doctorate in Genetic Epidemiology from the University of London. In 1980 Dr. Easton was recruited to a research fellow position at the Institute of Cancer Research. In 1995, Dr. Easton moved to Cambridge to become director of the Cancer Research Genetic Epidemiology Unit.

Easton will give an award lecture entitled, "Recent Developments in Genetic Susceptibility to Breast Cancer," on Thursday, December 11, 2008, at 11:30 a.m. CST, during the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, Texas.
-end-
For a high resolution photograph of Douglas Easton, Ph.D., please contact Megan Davies at (267) 646-0612 or megan.davies@aacr.org.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, with the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances into the clinic. The 31st Annual Symposium is expected to draw more than 8,500 participants from more than 80 countries.

American Association for Cancer Research

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.